Background: Systematic approaches to stakeholder-informed research prioritization are a central focus of comparative effectiveness research. Genomic testing in cancer is an ideal area to refine such approaches given rapid innovation and potentially significant impacts on patient outcomes.
W
ith rapid technological innovation, competing interests, and a complex health care system, prioritizing research for evidence generation in health care is not easy. To improve the likelihood that stakeholders' needs are met in an environment of constrained research resources, a research prioritization process informed by stakeholder perspectives may offer significant value and is a central theme of comparative effectiveness research (CER). [1] [2] [3] [4] Genomic testing in cancer is an ideal area to refine such approaches given the rapid pace of innovation and potentially significant impacts on patient outcomes. Genomic tests, defined herein as tests that detect genomic variation directly or in downstream molecular markers, are especially important in the realm of oncology due to the role of inherited and acquired genetic variation in tumor development, molecular classification of cancer subtypes, and proliferation of a wide array of targeted therapies.
We describe the development and methods of a systematic and stakeholder-driven approach to prioritizing genomic tests in oncology for evaluation in a future comparative study. To our knowledge, this is one of the first undertakings to incorporate a systematic literature review, expert analysis, and external stakeholder input to inform research prioritization in collaboration with a clinical trials consortium.
METHODS

CANCERGEN
The Center for Comparative Effectiveness Research in Cancer Genomics (CANCERGEN) is a consortium including the Fred Hutchinson Cancer Research Center (FHCRC), SWOG one of the largest cancer clinical trials consortium in the United States, the University of Washington (UW), and the Center for Medical Technology and Policy (CMTP)-a nonprofit organization involved in CER and stakeholder engagement activities. The CANCERGEN structure incorporates an external stakeholder group, and the overall goal of CANCERGEN is to facilitate prioritization and the rapid design and implementation of prospective CER studies of genomic tests.
We developed a process to identify and select candidate genomic tests for presentation to stakeholders and a process for prioritization based on stakeholder input (Fig. 1) .
Landscape Analysis
We refer to our process to identify genomic assays through evaluation of the literature, together with domainspecific expert consultation, as a "landscape analysis," rather than as a "horizon scan." [5] [6] [7] Horizon scanning efforts generally focus on interventions at the clinical horizon, and may not include expert review; our landscape analysis includes interventions still in the research phase and therefore includes a larger range of technologies, coupled with expert consultation.
The unit of our search was studies of genomic and protein biomarkers in oncology that could be used for prediction (patient response to a particular therapy) and/or prognostication (patient disease prognosis). To ensure maximum population impact and manage the scope of the analysis, we limited our initial search to the 5 most prevalent cancers: lung, breast, colorectal, bladder, and prostate. However, tests outside these specific areas were included if they were identified by experts or collaborators.
The peer-reviewed literature search conducted in Medline was limited to the last 5 years (2004-2009); assays described in peer-reviewed published articles before this time with a high degree of importance should already be in development or have further evidence published within our 5-year time window. We limited the search to "core" clinical journals ("jsubsetaim," Abridged Index Medicus).
We searched the gray literature, 8 including oncology conference proceedings for 2 years before including studies that may not yet reached the peer-reviewed literature. We also reviewed evidence reports and topics of investigation from organizations such as the Early Detection Research Network and Evaluation of Genomic Applications in Practice and Prevention. 7 CANCERGEN investigators identified 1 independent expert at the Fred Hutchinson Cancer Research Center and University of Washington in each of the 5 cancer areas, to whom a list of studies was sent, after applying the secondround exclusion criteria (described below). Experts were asked to rate the potential health care impact of the genomic technologies as well as provide feedback on any potential tests our landscape process failed to identify. We also elicited expert input from SWOG leadership, including diseasespecific committee members on tests of potential interest, as well as external stakeholder input for identification of tests.
Inclusion/Exclusion Criteria
Exclusion criteria were applied in 4 rounds. First, studies were excluded if they were nonquantitative reviews, did not include predictive or prognostic endpoints, and were not associated with any genomic tests. Second, studies that were not validated, study size too small (n < 50), prediction/ prognostication effect uncertain, and study not validated (not replicated in independent, separate finding) were excluded. Third-round exclusion criteria increased the stringency for acceptance in terms of trial size (n > 90), clinical impact on affected population, predictive rather than solely prognostic tests, and those interventions with large randomized controlled trials already in progress. Fourth-round inclusion/exclusion criteria for final selection included strength of biomarker validity, the potential for health care system impact, availability of patients for trials, SWOG investigator expertise and interest in subject area, relevance to current clinical development programs, availability of trial funding, and evidentiary gaps. These criteria were developed iteratively based upon the studies identified rather than being prespecified.
Stakeholder Selection Criteria
An external stakeholder advisory group (ESAG) was formed to engage stakeholders in the evidence generation and feedback process. Potential categories for stakeholder participation (patient/consumer, payer, clinician, policy maker/regulator, industry) were established requiring nominees who were senior-level members within their affiliated organization and possessed a working knowledge of genetics, personalized medicine, and/or oncology. Practical experience in evaluation of technology including genomic tests was also desirable.
Stakeholder Education and Prioritization Framework
We developed a prioritization framework modeled on the approach used by Evaluation of Genomic Applications in Practice and Prevention, an evidenced-based recommendation group for genomic tests, and refined these with the input of the external stakeholder group. [9] [10] [11] One-page test-target profiles (TTPs) were created summarizing these 9 criteria alongside more detailed topic briefs of 3-5 pages. The TTPs and topic briefs were sent to stakeholders approximately 2 weeks ahead of an in-person meeting.
Prioritization Process
Before the inperson meeting, stakeholders were asked to rank tests in order of importance. At the meeting, each of the tests was presented by the investigator who led the preparation of the respective TTP and topic brief. Stakeholders could bring up tests of particular interest to them, not previously identified through the landscape analysis and/or expert input. After all genomic applications were discussed, stakeholders were asked to again rank the tests in terms of research prioritization. A written meeting summary was shared with the entire ESAG and a follow-up teleconference was held 2 weeks after meeting with those members who were unable to attend inperson. A third round of voting on prioritization was conducted online immediately after the teleconference. A modified Delphi procedure 12 with an electronic audience polling system was used to obtain stakeholder responses throughout the prioritization process.
RESULTS
Landscape Analysis
The Medline search identified 199 studies; 436 studies were identified through the gray literature. These 635 studies were then narrowed to 188 studies based on the first set of exclusion criteria (first round) and to 49 studies by applying the second-round exclusion criteria. The third-round exclusion criteria narrowed the number of unique tests to 9. After joint consultation with SWOG leadership and application of the fourth-round inclusion/exclusion criteria, 6 tests remained for presentation to stakeholders (Fig. 2) .
Stakeholder Composition and Prioritization Process
Thirty-one total members were identified of which 13 were recruited; 2 of 4 from patients and consumers, 3 of 6 from health care providers, 2 of 6 from industry, 3 of 6 from purchasers and producers, and 3 of 9 from policy makers and regulators. The domains of the prioritization framework (Fig. 3) included population impact; current standard of care strength of association (analytical and clinical validity); potential clinical benefits, potential clinical harms, economic impacts, evidence of need clinical trial feasibility; and market factors (reimbursement status). The 6 tests selected for presentation to stakeholders (for which TTPs and topic briefs were prepared) are shown in Table 1 . Eight of 13 ESAG members attended the inperson meeting and voted; in the follow-up teleconference all 13 members of the external stakeholder group submitted their votes.
Genomic Tests
The 3 top ranked tests were: (1) EGFR mutation testing for erlotinib maintenance therapy after first-line chemotherapy in NSCLC; (2) ERCC1 expression testing for platinum-based adjuvant therapy in resected NSCLC; and (3) CEA, CA15-3/CA27.29 tumor markers for detection of breast cancer recurrence after primary therapy (1, 2, 3 in Table 1 ). Prospective studies and designs in these areas are now in different stages of preparation/submission.
DISCUSSION Implications
The processes developed here leveraged wide-ranging expertise coupled with stakeholder involvement in directing a research prioritization effort in CER. Our experience indicating the following aspects are valuable in stakeholderinformed CER prioritization: (1) systematic searches with 
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explicit inclusion/exclusion criteria and expert input; (2) diverse stakeholder group with unique backgrounds, opinions and perspectives; (3) a formal prioritization framework including explicit domains; (4) concise stakeholder educational materials; (5) a ranking methodology involving multiple rounds of feedback and reevaluation; and (6) early involvement of external stakeholders and leaders within the research organization. Our findings also suggest that the use of expert consultation to identify technologies in the landscape analysis may be more efficient, as interaction with SWOG experts would have independently identified 4 of 6 of the candidate tests presented to stakeholders. However, a systematic approach may carry greater validity with stakeholders. Additional research is needed to identify an optimal combination of systematic and expert-informed landscape analysis.
The implications of our study in regard to cancer genomics are as follows: only a small number of tests (9 in the third round and 6 in the fourth round) passed our inclusion/ exclusion criteria, suggesting that only a handful of genomic tests not yet already being evaluated are candidates for a large scale prospective clinical study. Notably, stakeholder involvement was influential in highlighting the priority of breast cancer tumor markers, which have been in use in practice for many years but lack high-quality evidence supporting their benefit.
Following these efforts, the CANCERGEN team has designed and submitted a prospective cohort study for EGFR testing in lung cancer, and study design is underway for breast cancer tumor markers. Furthermore we are conducting a feasibility analysis on ERCC1 testing in lung cancer, with preliminary studies on patient reported outcomes and preferences underway.
Limitations
There are several limitations of our study worth noting. Our landscape analysis was built upon studies that were published and accessible to us. However, as many studies are not published our results may incorporate a publication or reporting bias. CANCERGEN investigators, rather than stakeholders, were responsible for developing and application of inclusion/exclusion criteria. However, given the large range of studies analyzed and the iterative nature of inclusion/exclusion criteria developed, it would not be pragmatic and timely to engage stakeholders for a discussion of all studies.
We confined our literature search to core clinical journals and the 5 most prevalent cancers; a search of the entire literature might have revealed promising tests, but this was too resource and time intensive to carry out. A search of Medline without restriction to core clinical journals yielded over 4000 studies. We sought to mitigate the possibility of missing promising tests by the use of expert input.
We adopted an approach of bringing together diverse stakeholders consistent with CER principles; however, these stakeholders may bring in unique perspectives. By supporting an open discussion in a neutral forum we sought to bring out these opinions, allowing a constructive exchange of ideas and concerns, where specific interests and perspectives could be examined. Although the same stakeholder group was polled consistently throughout the process, the stakeholder group was too small to quantitatively assess patterns in the voting. Lastly, the process described above relied on qualitative evaluation of the potential value of research; we are currently working on formal value of information (or value of research) calculations to derive quantitative estimates for the top 3 candidates.
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CONCLUSIONS
We developed a CER-informed approach that provides diverse stakeholders a process for prioritizing research into genomic tests. SWOG, as one of the leading publically funded cancer cooperative groups, is actively exploring the use of comparative effectiveness principles and expertise in understanding how to better design and conduct relevant clinical trials that help better prevent, diagnose, or treat people. Further research is needed to develop approaches for integration with existing prioritization mechanisms. 4 EGFR gene copy number (FISH) testing and cetuximab therapy in advanced NSCLC 17, 18 5 GEP in multiple myeloma 19 6 BRAF mutation testing in colorectal cancer to guide use of cetuximab and panitumumab 20, 21 CA indicates cancer antigen; CEA, carcinoembryonic antigen; FISH, fluorescence in situ hybridization; GEP, gene expression profile; NSCLC, non-small-cell lung cancer.
